1. Home
  2. TVTX vs CSTM Comparison

TVTX vs CSTM Comparison

Compare TVTX & CSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Travere Therapeutics Inc.

TVTX

Travere Therapeutics Inc.

HOLD

Current Price

$40.41

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Logo Constellium SE (France)

CSTM

Constellium SE (France)

HOLD

Current Price

$29.47

Market Cap

3.4B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
TVTX
CSTM
Founded
N/A
2010
Country
United States
France
Employees
N/A
11500
Industry
Biotechnology: Pharmaceutical Preparations
Metal Fabrications
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
3.4B
IPO Year
2013
2012

Fundamental Metrics

Financial Performance
Metric
TVTX
CSTM
Price
$40.41
$29.47
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
14
4
Target Price
$40.46
$30.75
AVG Volume (30 Days)
2.2M
2.1M
Earning Date
05-07-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
92.89
405.26
EPS
N/A
1.92
Revenue
N/A
$8,449,000,000.00
Revenue This Year
$43.88
$21.46
Revenue Next Year
$33.16
$0.50
P/E Ratio
N/A
$15.45
Revenue Growth
N/A
15.19
52 Week Low
$13.88
$8.24
52 Week High
$43.31
$31.20

Technical Indicators

Market Signals
Indicator
TVTX
CSTM
Relative Strength Index (RSI) 69.56 62.65
Support Level $32.62 $13.79
Resistance Level $41.44 N/A
Average True Range (ATR) 2.17 1.36
MACD 1.26 0.26
Stochastic Oscillator 82.25 79.20

Price Performance

Historical Comparison
TVTX
CSTM

About TVTX Travere Therapeutics Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.

About CSTM Constellium SE (France)

Constellium SE is engaged in the development, manufacture and sale of a broad range of high value-added specialty rolled and extruded aluminum products to the aerospace, space, defense, packaging, automotive, commercial transportation and general industrial end-markets. Its business model is to add value by converting aluminum into semi-fabricated and, in some instances, fully-fabricated alloyed aluminum products that meet stringent and performance-critical requirements from customers. It operates through three segments: Aerospace & Transportation Operating Segment, Packaging & Automotive Rolled Products Operating Segment, and Automotive Structures & Industry Operating Segment. It serves Aerospace, Packaging and Automotive and operates in the United States, France, Germany and others.

Share on Social Networks: